- Could You Spot the Silent Symptoms of Stress?
- Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
- Key Therapy Equally Effective for Women, Men With Narrowed Leg Arteries
- Doctors Describe Texas Dairy Farm Worker’s Case of Bird Flu
- Does Preschool Boost Kids’ Long-Term Academic Success? Study Finds Mixed Results
- AI Might Spot Rare Diseases in Patients Years Earlier
- An Orangutan Healed Himself With Medicinal Plant
- Quit-Smoking Meds Not Working for You? Try Upping the Dose
- Fewer Americans Are Suffering Most Dangerous Form of Heart Attack
- Even Skipping Meat for One Meal Helps Liver Disease Patients
Brintellix Approved for Major Depressive Disorder
TUESDAY, Oct. 1Brintellix (vortioxetine) has been approved by the U.S. Food and Drug Administration to treat adults with major depressive disorder, often referred to as depression.
The disorder may have symptoms including lack of interest in usual activities, weight or appetite changes, sleep problems, feelings of guilt or worthlessness, lack of concentration and thoughts of suicide.
In seven clinical studies, Brintellix proved effective in treating depression and in preventing future episodes, the FDA said in a news release. The most common side effects observed included nausea, constipation and vomiting.
Brintellix has a boxed label warning that antidepressants can raise the risk of suicidal thoughts among some users, especially among children, adolescents and adults aged 18 to 24. Doctors should carefully monitor users of Brintellix and similar drugs, especially during initial treatment, the FDA advised.
Brintellix is marketed by Takeda Pharmaceuticals and Lunbeck, both based in Deerfield, Ill.
More information
The U.S. National Institute of Mental Health has more about depression.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.